M Berenguer

Summary

Country: Spain

Publications

  1. ncbi Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease
    Marina Berenguer
    Hospital Universitario La Fe, Servicio de Gastroenterología y Hepatología, Avda Campanar 21 Valencia 46009, Spain
    Clin Liver Dis 7:631-50, vii. 2003
  2. ncbi Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
    Marina Berenguer
    Hepatogastroenterology Service, Hospital Universitari La Fe, Valencia, Spain
    Liver Transpl 12:1067-76. 2006
  3. doi Treatment of chronic hepatitis C in hemodialysis patients
    Marina Berenguer
    Hepatogastroenterology Service, Hospital La Fe, Facultad de Medicina de la Universidad de Valencia, Valencia, Spain
    Hepatology 48:1690-9. 2008
  4. doi Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment
    Marina Berenguer
    University Valencia, Dept of Medicine, Hepatology and Liver Transplantation Unit, La Fe Hospital and Ciberehd, National network center for hepatology and gastroenterology research, Instituto de Salud Carlos III, Spain
    J Hepatol 58:1028-41. 2013
  5. doi Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: role of an aggressive approach
    Marina Berenguer
    Liver Transplantation and Hepatology Unit, La Fe Hospital, Valencia, Spain
    Liver Transpl 19:69-77. 2013
  6. doi Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy
    Marina Berenguer
    Liver Transplantation and Hepatology Unit, La Fe Hospital, Valencia, Spain
    J Hepatol 56:1310-6. 2012
  7. doi Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation
    M Berenguer
    Hepatogastroenterology Service, Hospital La Fe, Valencia, Spain
    Am J Transplant 8:679-87. 2008
  8. ncbi Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients
    Marina Berenguer
    Hepatogastroenterology Service, Hospital Universitario La Fe, Valencia, Spain
    Liver Transpl 12:762-7. 2006
  9. ncbi Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression
    Marina Berenguer
    Hepatogastroenterology Service, Servicio de Hepatogastroenterología, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
    J Hepatol 44:717-22. 2006
  10. ncbi Recurrent allograft disease: viral hepatitis
    Marina Berenguer
    Hospital Universitario La Fe, Servicio de Gastroenterología y Hepatología, Valencia, Spain
    Acta Gastroenterol Belg 68:337-46. 2005

Detail Information

Publications74

  1. ncbi Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease
    Marina Berenguer
    Hospital Universitario La Fe, Servicio de Gastroenterología y Hepatología, Avda Campanar 21 Valencia 46009, Spain
    Clin Liver Dis 7:631-50, vii. 2003
    ..In addition, viral infection recurs nearly universally leading to the development of chronic HCV in most recipients and progression to cirrhosis after a median of 9 to 12 years in a significant proportion of these recipients...
  2. ncbi Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
    Marina Berenguer
    Hepatogastroenterology Service, Hospital Universitari La Fe, Valencia, Spain
    Liver Transpl 12:1067-76. 2006
    ..The type of calcineurin inhibitor and history of prior non-response to IFN before LT do not influence the outcome of therapy. Severe rejection may lead to graft loss, a complication difficult to predict...
  3. doi Treatment of chronic hepatitis C in hemodialysis patients
    Marina Berenguer
    Hepatogastroenterology Service, Hospital La Fe, Facultad de Medicina de la Universidad de Valencia, Valencia, Spain
    Hepatology 48:1690-9. 2008
    ..In light of the results from these clinical trials, we herein review treatment guidelines and recommend strategies to help optimize the treatment of patients with ESRD...
  4. doi Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment
    Marina Berenguer
    University Valencia, Dept of Medicine, Hepatology and Liver Transplantation Unit, La Fe Hospital and Ciberehd, National network center for hepatology and gastroenterology research, Instituto de Salud Carlos III, Spain
    J Hepatol 58:1028-41. 2013
    ....
  5. doi Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: role of an aggressive approach
    Marina Berenguer
    Liver Transplantation and Hepatology Unit, La Fe Hospital, Valencia, Spain
    Liver Transpl 19:69-77. 2013
    ....
  6. doi Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy
    Marina Berenguer
    Liver Transplantation and Hepatology Unit, La Fe Hospital, Valencia, Spain
    J Hepatol 56:1310-6. 2012
    ..We aimed at assessing whether changes in treatment policy, that is starting therapy at lesser stages of fibrosis, have resulted in improved efficacy...
  7. doi Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation
    M Berenguer
    Hepatogastroenterology Service, Hospital La Fe, Valencia, Spain
    Am J Transplant 8:679-87. 2008
    ..6/16; p = 0.06). The 5-year risk of graft decompensation was higher in NRs (33% vs. 16%; p = 0.04). Antiviral therapy is associated with improved long-term outcome in recurrent HCV...
  8. ncbi Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients
    Marina Berenguer
    Hepatogastroenterology Service, Hospital Universitario La Fe, Valencia, Spain
    Liver Transpl 12:762-7. 2006
    ..In conclusions, the short-term posttransplantation course of hepatitis C is not related to the calcineurin inhibitor used...
  9. ncbi Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression
    Marina Berenguer
    Hepatogastroenterology Service, Servicio de Hepatogastroenterología, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
    J Hepatol 44:717-22. 2006
    ..To determine whether the implementation of specific measures aimed at reducing or avoiding negative predictive variables is associated with an improvement in the outcome of recurrent hepatitis C...
  10. ncbi Recurrent allograft disease: viral hepatitis
    Marina Berenguer
    Hospital Universitario La Fe, Servicio de Gastroenterología y Hepatología, Valencia, Spain
    Acta Gastroenterol Belg 68:337-46. 2005
    ....
  11. ncbi Treatment of hepatitis C after liver transplantation
    Marina Berenguer
    Hospital Universitario La Fe, Servicio de Medicina Digestiva, Avenida Campanar 21, Valencia, 46009 Spain
    Clin Liver Dis 9:579-600, vi. 2005
    ..Alternatively, the implementation of measures aimed at reducing or avoiding factors known to be associated with an aggressive recurrence is an additional strategy that needs to be explored...
  12. ncbi Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy
    Marina Berenguer
    Hepato Gastroenterology Service, Pathology Service, Hospital Universitario La Fe, Avda Campanar 21, 46009 Valencia, Spain
    Eur J Gastroenterol Hepatol 16:1207-12. 2004
    ..Little is known, however, about the efficacy and risk of adverse effects when it is used in general clinical practice...
  13. ncbi Viral hepatitis B, C and D
    M Berenguer
    Hospital Universitario La Fe, Servicio de Medicina Digestiva, Valencia, Spain
    Acta Gastroenterol Belg 67:197-205. 2004
  14. ncbi [Management of hepatitis C virus infection in liver transplantation]
    Marina Berenguer
    Servicio de Medicina Digestiva Hospital Universitario La Fe Valencia España
    Gastroenterol Hepatol 29:422-7. 2006
    ..Adverse effects, such as cytopenia and even induction of rejection, are the main limitation and lead to premature withdrawal in 30% of patients...
  15. ncbi Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis
    Marina Berenguer
    Hepatogastroenterology Service, Hospital Universitari La Fe, Valencia, Spain
    Liver Transpl 13:21-9. 2007
    ..Unfortunately, data on the severity of recurrence and effect on viremia are scarce. Well-designed randomized prospective studies are needed to determine whether there are differences between the 2 CNIs regarding these specific variables...
  16. ncbi Management of hepatitis C virus in the transplant patient
    Marina Berenguer
    Universidad de Medicina, Hospital Universitario La Fe, Servicio de Medicina Digestiva, CIBERehd, Avda Campanar 21, Valencia, 46009 Spain
    Clin Liver Dis 11:355-76. 2007
    ..This review highlights the available strategies to improve outcome, including modification of factors that affect disease progression and the efficacy of antiviral therapy...
  17. doi Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin
    Marina Berenguer
    Hepatogastroenterology Service, Hospital La Fe, Valencia, Spain and CIBEREHD, Spain
    J Hepatol 49:274-87. 2008
    ..EVR at 3 months of treatment should be considered an important predictor of treatment outcome...
  18. doi Risk of extended criteria donors in hepatitis C virus-positive recipients
    Marina Berenguer
    Hospital Universitario La Fe, Valencia, Spain
    Liver Transpl 14:S45-50. 2008
    ..Although a donor graft biopsy is not required if an extended criteria donor is used, it is highly recommended when hepatitis C virus-positive donors, donation after cardiac death, or multiple extended criteria donor factors are involved...
  19. doi Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis
    Marina Berenguer
    Hepatogastroenterology Service, Hospital Universitari La Fe, Valencia, Spain
    Liver Transpl 15:738-46. 2009
    ..In conclusion, the efficacy of antiviral therapy with PegIFN-Rbv has worsened over time, at least in our center. The increase in donor age and greater proportion of patients treated at advanced stages of disease are potential causes...
  20. doi Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients
    Marina Berenguer
    Hospital Universitari La Fe, Avda Campanar, Valencia, Spain
    Transplantation 90:1204-9. 2010
    ..There is a paucity of good studies evaluating the impact of calcineurin inhibitors on posttransplantation outcome in hepatitis C virus (HCV)-infected liver transplant (LT) recipients...
  21. doi Hot topic in hepatitis C virus research: the type of immunosuppression does not matter
    Marina Berenguer
    Hepatology Unit, La Fe Hospital, Valencia, Spain
    Liver Transpl 17:S24-8. 2011
    ..5. There are no convincing data for modifying the type of immunosuppression before antiviral therapy is started...
  22. ncbi Hepatitis C and fibrosis
    V Aguilera
    Service of Digestive Medicine, University Hospital La Fe, Valencia, Spain
    Rev Esp Enferm Dig 96:402-8; 409-14. 2004
  23. ncbi Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients
    Marina Berenguer
    Hepatogastroenterology Service, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
    Hepatology 36:202-10. 2002
    ..In conclusion, patient survival is lower among HCV+ recipients than among HCV- ones and has been decreasing in recent years. The aging of donors is a major contributor to this worse outcome...
  24. ncbi A model to predict severe HCV-related disease following liver transplantation
    Marina Berenguer
    Hepato Gastroenterology Service, Pathology Service, Hospital Universitario La Fe, Valencia, Spain
    Hepatology 38:34-41. 2003
    ..Accuracy of the model is not perfect (c-statistic 0.80), probably reflecting the complexity of HCV in the liver transplant setting...
  25. ncbi Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis
    Marina Berenguer
    Hepatogastroenterology Service, Hospital Universitari La Fe, Valencia, Spain
    Liver Transpl 9:228-35. 2003
    ..The outcome of retransplantation for HCV cirrhosis of the first graft is very poor because of multiple complications. The severity of recurrent HCV disease in the second graft seems to be related to that observed in the first graft...
  26. ncbi Host and donor risk factors before and after liver transplantation that impact HCV recurrence
    Marina Berenguer
    Servicio de Medicina Digestiva, Hospital Universitario La Fe, Valencia, Spain
    Liver Transpl 9:S44-7. 2003
    ..5. Additional host-related variables predictive of outcome include the immunogenetic background, the timing of recurrence, and the early histologic findings...
  27. ncbi Natural history of recurrent hepatitis C
    Marina Berenguer
    Hepato Gastroenterology Service, La Fe Hospital, Valencia, Spain
    Liver Transpl 8:S14-8. 2002
    ....
  28. ncbi Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?
    Marina Berenguer
    Hepato Gastroenterology Service, Hospital Universitario La Fe, Valencia, Spain
    Liver Transpl 9:1152-8. 2003
    ..Based on these findings, we recommend continuing protocol biopsies and evaluating potential antiviral therapy in transplant recipients with evidence of some fibrosis (even if it is only portal)...
  29. ncbi [Inmunosuppression and liver transplantation in patients with hepatitis C virus infection]
    M Berenguer
    Servicio de Medicina Digestiva, Hospital Universitario La Fe, Valencia, Spain
    Gastroenterol Hepatol 25:276-9. 2002
  30. ncbi Are posttransplantation protocol liver biopsies useful in the long term?
    M Berenguer
    Hepatogastroenterology Service, Hospital Universitario La Fe, Valencia, Spain
    Liver Transpl 7:790-6. 2001
    ..Conversely, given the rarity of abnormal histological findings, protocol liver biopsies should be questioned in non-HCV-infected transplant recipients with normal transaminase values...
  31. ncbi Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection
    M Berenguer
    Hepatogastroenterology Service, Hospital Universitario La Fe, Valencia, Spain
    J Hepatol 28:756-63. 1998
    ....
  32. ncbi High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes
    M Prieto
    Hepatogastroenterology Service, Hospital Universitario La Fe, Valencia
    Hepatology 29:250-6. 1999
    ..First-year liver biopsies may help to sooner identify patients at the highest risk, improving further patient management...
  33. ncbi Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation
    M Berenguer
    Hepatogastroenterology Service, Hospital Universitari La Fe, Valencia, Spain
    Hepatology 32:852-8. 2000
    ..The natural history of clinically compensated HCV-graft cirrhosis is shortened when compared with immunocompetent patients. If retransplantation is considered, it should be performed promptly once decompensation develops...
  34. ncbi Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation
    F X López-Labrador
    Microbiology Exp Immunology, Research Centre, Hospital Universitari La Fe, Valencia, Spain
    J Viral Hepat 13:104-15. 2006
    ..In the liver transplant setting, when the immune response is severely compromised, other mechanisms are probably more important in determining hepatitis C progression...
  35. ncbi Liver transplantation in hepatitis C. A Spanish multi-centre experience
    M Prieto
    Hospital Universitario La Fe, Valencia, Spain
    Eur J Gastroenterol Hepatol 10:771-6. 1998
    ..The purpose of this retrospective survey was to determine the prevalence and outcome of hepatitis C virus (HCV) infection in cirrhotic patients undergoing liver transplantation (OLT) in Spain in 1992...
  36. ncbi Famciclovir treatment in transplant recipients with HBV-related liver disease: disappointing results
    M Berenguer
    Hepatogastroenterology Service, Hospital Universitario La Fe, Valencia, Spain
    Am J Gastroenterol 96:526-33. 2001
    ..Histological improvement was only observed in one patient. CONCLUSION: Famciclovir alone appears of limited efficacy in the treatment of HBV infection after liver transplantation...
  37. ncbi De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population
    M Prieto
    Hepatogastroenterology, Hospital Universitario La Fe, Valencia, Spain
    Liver Transpl 7:51-8. 2001
    ..In the current era of donor shortage, this policy would allow adequate use of such donors...
  38. ncbi [Incidence of de novo neoplasms after liver transplantation]
    M Berenguer
    Servicio de Medicina Digestiva, Hospital Universitario La Fe, Valencia
    Med Clin (Barc) 111:481-4. 1998
    ..De novo malignancy developing after transplantation constitutes a well-known complication or organ transplantation, mainly described among renal recipients...
  39. ncbi [Old donors in liver transplantation for chronic hepatitis C]
    V Aguilera
    Servicio de Medicina Digestiva, Hospital La Fe, CIBERehd
    Rev Esp Enferm Dig 99:581-7. 2007
    ..The identification of factors associated with this poorer outcome may improve results. While donor age has been identified as one of the most important factors, the actual options to modify this variable are limited...
  40. doi Indications for and results of liver retransplantation
    R Torres-Quevedo
    Unit of Surgery and Liver Transplantation, University Hospital La Fe, Valencia, Spain
    Transplant Proc 41:1016-7. 2009
    ..It becomes necessary to define the minimal acceptable results that patient can benefit from LReTx...
  41. doi Liver transplantation and hepatitis C
    A Rubin
    Hepatology liver transplantation unit, Digestive Medicine Service, and CIBEREHD, National network center for hepatology and gastroenterology research, Hospital Universitari I Politècnic La Fe, Instituto de Salud Carlos III, Bulevar Sur S N, 46026 Valencia, Spain
    Clin Res Hepatol Gastroenterol 35:805-12. 2011
    ..Retransplantation (RT) is the last option for the small subset of patients with allograft failure due to HCV recurrence who fulfil minimum criteria based on RT survival models...
  42. doi Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis
    Victoria Aguilera
    Liver Surgery and Transplant Unit, Hospital La Fe de Valencia, Valencia, Spain
    Liver Transpl 15:79-87. 2009
    ..A greater use of antiviral therapy in the mixed group may explain these differences. The incidence of metabolic complications and de novo tumors was greater in the alcohol groups...
  43. ncbi Antiviral therapy in patients with HCV-cirrhosis
    Josep Melero
    Hepatology Unit, La Fe Hospital and Ciberehd, Valencia, Spain
    Ann Hepatol 8:292-7. 2009
    ..In conclusion, antiviral therapy is an option for cirrhotic patients who have a good liver function but should not be recommended in patients with Child-Pugh-Turcotte class C, due to a high risk of severe complications...
  44. doi Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients
    Salvador Benlloch
    Liver Unit, Department of Hepatogastroenterology, La Fe University Hospital, Valencia, Spain
    Liver Transpl 15:1798-807. 2009
    ..Because the index distinguishes a subgroup of HCV LT patients with a low probability of having SF, PLB would be avoided in those patients...
  45. ncbi Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?
    Angel Moya
    Department of Surgery, Hospital Universitario La Fe, Valencia, Spain
    Liver Transpl 8:1020-7. 2002
    ..001). Although LT still remains an adequate indication for HCC in centers with high prevalence of HCV infection and short waiting times, both tumor and HCV-related recurrent diseases hamper significantly the outcomes of these patients...
  46. doi Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma
    Mauricio Silva
    Department of Hepatogastroenterology, Hospital Universitario La Fe, Valencia, Spain
    Liver Transpl 14:1449-60. 2008
    ..001) increased the risk of recurrence. The expansion to up to 3 nodules, each up to 5 cm, and a cumulative tumor burden </= 10 cm did not result in a reduction of survival in comparison with patients who had tumors within the MC...
  47. ncbi Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C
    F Xavier López-Labrador
    Microbiology, Hospital Universitari La Fe and Centro de Investigación, Valencia, Spain
    Liver Transpl 10:217-27. 2004
    ....
  48. ncbi Contribution of obesity to hepatitis C-related fibrosis progression
    Vicente Ortiz
    Hepatogastroenterology Service, Hospital Universitari La Fe, Valencia, Spain
    Am J Gastroenterol 97:2408-14. 2002
    ....
  49. ncbi Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C
    F Xavier López-Labrador
    Department of Medicine Gastroenterology and Hepatology Stanford University School of Medicine, Stanford, California, USA
    J Med Virol 72:575-85. 2004
    ..These data may be useful to improve T-cell assays using HCV NS3 peptides, taking into account the genetic diversity of this virus...
  50. ncbi The use of class-I HLA tetramers for the detection of hepatitis C virus NS3-specific CD8(+) T cells in patients with chronic infection
    F Xavier López-Labrador
    Department of Medicine Gastroenterology and Hepatology, Stanford University School of Medicine, CA 94305, USA
    J Immunol Methods 287:91-9. 2004
    ..New methods to detect virus-specific T-cell responses have recently been developed. Several human leukocyte antigen (HLA)-peptide tetramers for the detection of hepatitis C virus (HCV)-specific CD8(+) T cells are under evaluation...
  51. doi Comparative prospective study of two liver graft preservation solutions: University of Wisconsin and Celsior
    Rafael López-Andujar
    Hepatic Surgery and Liver Transplant Unit, La Fe University Hospital, Valencia, Spain
    Liver Transpl 15:1709-17. 2009
    ..In conclusion, this study shows that CS is as effective as UWS in liver preservation...
  52. ncbi De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?
    Salvador Benlloch
    Department of Hepato Gastroenterology, Hospital Universitario La Fe, Valencia, Spain
    Am J Transplant 4:596-604. 2004
    ..Risk factors for tumor development include alcohol, HCV and possibly strong immunosuppression...
  53. ncbi Post-liver transplantation medical complications
    Rosalba Moreno
    Hospital de Especialidades Centro Médico Nacional SXXI, IMSS, Servicio de Gastroenterologia, Valencia, Spain
    Ann Hepatol 5:77-85. 2006
    ..This review summarizes available data about medical complications of the early and long term follow up...
  54. ncbi What determines the natural history of recurrent hepatitis C after liver transplantation?
    Marina Berenguer
    Hospital Universitario La Fe, Servicio de Medicina Digestiva, Avda Campanar 21, Valencia 46009, Spain
    J Hepatol 42:448-56. 2005
  55. ncbi Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index
    Salvador Benlloch
    Hepato Gastroenterology Service, Hospital Universitario La Fe, Valencia, Spain
    Liver Transpl 11:456-62. 2005
    ..In conclusion, in the LT setting, a simple fibrosis index is useful to select HCV-infected patients with a very low risk of significant fibrosis in whom protocol liver biopsies may be avoided...
  56. ncbi [Study of patients referred for elevated ferritin levels and/or transferrin saturation: significance of non-alcoholic fatty liver disease]
    F Perez-Aguilar
    Servicio de Medicina Digestiva, Hospital Universitario La Fe, Valencia, Spain
    Gastroenterol Hepatol 27:508-14. 2004
    ..To determine the etiology of increased ferritin concentrations and/or transferrin saturation in patients in whom classical causes were ruled out...
  57. ncbi [Liver retransplantation: outcome analysis in 50 patients]
    Carmen Landaverde
    Servicio de Medicina Digestiva, Hospital La Fe, Valencia, Espana
    Med Clin (Barc) 124:721-5. 2005
    ....
  58. ncbi Budd-Chiari syndrome caused by membranous obstruction of the inferior vena cava associated with coeliac disease
    F Martinez
    Department of Gastroenterology and Hepatology, Hospital La Fe, Avenida de Campanar 21, 46009 Valencia, Spain
    Dig Liver Dis 36:157-62. 2004
    ..A percutaneous balloon angioplasty was performed, with satisfactory outcome...
  59. ncbi Non-alcoholic statohepatitis: physiopathological, clinical and therapeutic implications
    F Pérez Aguilar
    Service of Digeste Medicine, Hospital Universitario La Fe, Valencia, Spain
    Rev Esp Enferm Dig 96:628-39; 440-8. 2004
  60. ncbi [Candidate selection for liver transplantation]
    Martin Prieto
    Servicio de Medicina Digestiva, Hospital Universitario La Fe, Valencia, Spain
    Gastroenterol Hepatol 30:42-53. 2007
    ..The present review analyzes the most frequent contraindications to transplantation, as well as the most important aspects of pretransplantation evaluation...
  61. ncbi Lessons learned from anatomic variants of the hepatic artery in 1,081 transplanted livers
    Rafael López-Andujar
    Hepatic Surgery and Liver Transplant Unit, La Fe University Hospital, Valencia, Spain
    Liver Transpl 13:1401-4. 2007
    ....
  62. ncbi [Acute acalculous cholecystitis associated with acute hepatitis A virus infection]
    Josep L Melero Ferrer
    Servei de Medicina Digestiva, Hospital Universitari La Fe, Valencia, Espana
    Gastroenterol Hepatol 31:433-5. 2008
    ..The patient underwent surgery. In the postoperative period, positive IgM antibody titers for HAV were obtained, confirming the diagnosis of HAV infection...
  63. ncbi Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors
    Fabio Piscaglia
    Department of Internal Medicine and Gastroenterology, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Eur J Gastroenterol Hepatol 18:1255-61. 2006
    ....
  64. ncbi Treatment of recurrence of hepatitis B in transplant patients
    Marina Berenguer
    Department of Veterans Affairs Medical Center, University of California, San Francisco, CA, USA
    J Hepatol 39:S190-3. 2003
  65. ncbi Hepatitis C and liver transplantation
    Rosalba Moreno
    Centro Médico Nacional SXXXI del IMSS, Hospital de Especialidades Bernardo Sepúlveda, Servico de Gastroenterologia, Cuauhtemoc, Mexico
    Ann Hepatol 1:129-35. 2002
    ..The groups involved those pretransplantation, post-transplant HCV infection, preventive early post-transplantation and with of recurrent hepatitis C...
  66. ncbi [Liver transplantation in patients with chronic viral hepatitis]
    Rosalba Moreno
    Servicio de Gastroenterología Hospital de Especialidades Centro Médico Nacional Siglo XXI, IMSS Mexico, D F
    Rev Gastroenterol Mex 70:180-91. 2005
    ..This review summarizes available data and highlights appropriate strategies to improve outcomes...
  67. ncbi Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006)
    Didier Samuel
    HepatoBiliary Centre, Inserm Paris XI U 785, Paul Brousse Hospital, APHP, Villejuif, France
    J Hepatol 45:127-43. 2006
  68. ncbi Treating hepatitis C infection in liver transplant recipients
    Norah A Terrault
    Department of Medicine Gastroenterology, University of California San Francisco, San Francisco, CA, USA
    Liver Transpl 12:1192-204. 2006
    ..Liver Transpl 12:1192-1204, 2006. (c) 2006 AASLD...
  69. ncbi Outcome of posttransplantation hepatitis C virus disease--is it the host, the virus, or how we modify the host and/or the virus?
    Marina Berenguer
    Liver Transpl 8:889-91. 2002
  70. ncbi Live donor liver transplantation for hepatitis C: new data, old story
    Marina Berenguer
    Liver Transpl 12:516-9. 2006
  71. ncbi Recurrent hepatitis C: worse outcomes established, interventions still inadequate
    Marina Berenguer
    Liver Transpl 13:641-3. 2007
  72. pmc Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfected patients
    F Xavier López-Labrador
    Public Health Department, Generalitat Valenciana and Evolutionary Genetics Unit, Institut Cavanilles de Biodiversitat i Biologia Evolutiva, University of Valencia, Apt Of 2085, E 46071 Valencia, Spain
    Virus Res 130:285-91. 2007
    ..Differences in immune regulation of HCV quasispecies in HIV coinfected individuals deserve further exploration to clarify the different outcomes of chronic hepatitis C noted between the immunocompromised and the immunocompetent host...
  73. ncbi Transplantation for alcoholic liver disease
    James Neuberger
    Liver Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, UK
    J Hepatol 36:130-7. 2002